-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Initiates Coverage On MapLight Therapeutics with Neutral Rating

Benzinga·10/06/2026 11:23:41
Listen to the news
Guggenheim analyst Delma Caiati initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Neutral rating.